Latest Europe News

Vmoto Limited reports a robust sales rebound in the final quarter of 2025, with a 68% jump in units sold and a near doubling of firm orders, underpinned by strategic partnerships and expanding manufacturing capacity.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Little Green Pharma Ltd is set to acquire Cannatrek Ltd in a transformative merger that will create one of the largest vertically integrated medicinal cannabis companies globally, with pro-forma FY25 revenue exceeding AUD 112 million.

Acadia Pharmaceuticals has received a negative vote from the European Medicines Agency’s committee on its application to market trofinetide for Rett syndrome in the EU, prompting plans for a re-examination request.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Vection Technologies has secured a $2.2 million defence contract for its new FEDRA edge data appliance, marking a significant step in its AI-powered military technology portfolio under a $22.3 million framework agreement.

Aura Energy has successfully raised A$20 million through a heavily oversubscribed placement, aiming to accelerate development at its Tiris Uranium Project amid rising global uranium demand.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.

Electro Optic Systems (EOS) addresses rumours about relocating its headquarters and stock listing to Europe, affirming no such decisions have been made despite strong growth in European defence markets.

ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.

Krakatoa Resources has reported significant high-grade gold and antimony assay results from its Phase 1 drilling at the Zopkhito Project in Georgia, alongside a 12-month extension to its option period. The company plans an expanded exploration program in 2026 aimed at delivering a JORC-compliant resource.